Table 4.
Two indicators of severity (proportion of cases reporting severe role impairment due to depression and proportion of cases reporting suicide ideation) among respondents with 12-month DSM-IV/CIDI MDD depending on presence or absence of comorbid anxiety disordersa in the WHO WMH Surveys
| Prevalence of severe role impairmentb when comorbid anxiety disorders are … | Prevalence of suicide ideationc when comorbid anxiety disorders are … | Number of respondents with 12-month MDD where comorbid anxiety disorders are … | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Present | Absent | Present | Absent | Present | Absent | |||||
| % | (s.e.) | % | (s.e.) | % | (s.e.) | % | (s.e.) | (n) | (n) | |
| I. Low/Middle Income | ||||||||||
| Brazil – São Paulo | 57.0* | (3.5) | 41.2 | (2.9) | 18.7* | (3.4) | 7.1 | (1.6) | (205) | (284) |
| Bulgaria | 51.7* | (6.9) | 41.5 | (5.2) | 8.7* | (4.5) | 16.1 | (6.7) | (54) | (91) |
| Colombia | 49.3* | (4.8) | 42.1 | (4.8) | 20.8* | (5.9) | 13.5 | (3.6) | (110) | (131) |
| Colombia – Medellin | 51.0 | (5.9) | 51.1 | (5.7) | 21.3 | (5.8) | 18.5 | (5.3) | (73) | (78) |
| Iraq | 71.8* | (5.0) | 36.3 | (4.8) | 11.8* | (5.9) | 4.7 | (1.8) | (81) | (101) |
| Lebanon | 63.3 | (7.0) | 64.5 | (5.5) | 5.3* | (3.8) | 9.2 | (3.9) | (49) | (77) |
| Mexico | 45.2* | (5.0) | 38.6 | (4.3) | 16.4 | (4.3) | 15.9 | (3.9) | (101) | (130) |
| Nigeria | 8.0 | (8.2) | 16.2 | (4.8) | 20.8 | (18.2) | 17.7 | (6.5) | (12) | (60) |
| Peru | 35.3 | (8.0) | 39.7 | (6.3) | 6.9* | (4.7) | 18.3 | (5.0) | (37) | (62) |
| PRCd – Beijing/Shanghai | 22.1 | (9.3) | 32.2 | (5.8) | 8.2 | (5.8) | 4.2 | (2.8) | (21) | (66) |
| PRCd – Shenzhen | 41.1* | (8.2) | 19.4 | (2.9) | 5.0 | (2.9) | 3.2 | (1.6) | (37) | (185) |
| Romania | 46.9 | (15.8) | 40.8 | (9.3) | 5.0 | (5.4) | 4.6 | (4.6) | (11) | (29) |
| Total | 61.5* | (1.5) | 41.9 | (1.3) | 15.2* | (1.8) | 9.4 | (1.0) | (791) | (1294) |
| II. High Income | ||||||||||
| Australia | 77.3* | (2.8) | 52.4 | (3.4) | 24.9* | (3.9) | 7.1 | (1.7) | (229) | (217) |
| Belgium | 66.0 | (12.6) | 52.4 | (9.6) | 12.7 | (5.2) | 10.9 | (5.0) | (39) | (67) |
| France | 67.2 | (8.4) | 49.3 | (7.9) | 19.3* | (6.3) | 7.0 | (2.8) | (68) | (89) |
| Germany | 64.5 | (9.6) | 54.2 | (8.7) | 19.1* | (6.2) | 2.1 | (1.5) | (55) | (54) |
| Israel | 70.8* | (6.6) | 51.2 | (3.3) | 15.3* | (5.5) | 9.7 | (2.0) | (48) | (232) |
| Italy | 59.8 | (11.8) | 53.6 | (8.9) | 10.8* | (4.4) | 5.0 | (2.4) | (51) | (67) |
| Japan | 68.9* | (9.4) | 28.5 | (6.1) | 32.7* | (11.0) | 6.9 | (3.6) | (25) | (56) |
| Netherlands | 68.1 | (14.7) | 55.7 | (9.4) | 19.0 | (7.2) | 14.1 | (9.0) | (40) | (81) |
| New Zealand | 73.2* | (2.3) | 56.2 | (2.6) | 28.9* | (3.3) | 14.7 | (2.3) | (370) | (365) |
| Northern Ireland | 62.6* | (4.6) | 51.1 | (4.8) | 14.7* | (3.7) | 1.2 | (0.9) | (110) | (109) |
| Poland | 56.5* | (8.4) | 41.7 | (5.3) | 18.5* | (7.0) | 8.4 | (3.3) | (36) | (87) |
| Portugal | 59.3* | (4.4) | 42.1 | (3.9) | 13.5* | (3.1) | 8.7 | (2.4) | (126) | (164) |
| Spain | 61.8 | (8.4) | 52.6 | (7.6) | 6.8 | (3.0) | 7.3 | (2.7) | (87) | (142) |
| Spain – Murcia | 50.8* | (7.5) | 36.4 | (4.6) | 15.2* | (6.0) | 6.8 | (2.9) | (45) | (109) |
| US | 67.0* | (2.4) | 46.0 | (3.0) | 21.5* | (2.4) | 7.8 | (1.7) | (375) | (271) |
| Total | 68.8* | (1.2) | 49.6 | (1.2) | 21.3* | (1.3) | 8.7 | (0.7) | (1704) | (2110) |
| III. Total | 64.4* | (1.0) | 46.0 | (0.9) | 19.5* | (1.1) | 8.9 | (0.6) | (2495) | (3404) |
*Significant difference depending on whether comorbid anxiety disorders are present v. absent at the 0.05 level, two-sided test.
aAnxiety disorders include generalised anxiety disorder, panic disorder with or without agoraphobia, agoraphobia without a history of panic disorder, specific phobia, social phobia, separation anxiety and post-traumatic stress disorder.
bRatings of severe or very severe on one or more SDS dimensions in the 1 month in the 12 before interview when the respondent's MDD was most severe.
cAt any time in the 12 months before interview.
dPeople's Republic of China.